AMMPS-LD RE-001, version 1.0

AMMPS-LD RE-001, version 1.0, dated 26/02/2026 — the Agency's framework guideline for taking regulatory decisions on the basis of another authority's work. A preface, a list of abbreviations, then sections I–VII: introduction, objectives, scope, the recognition-based routes, the domains of recognition, the regulatory authorities the AMMPS recognises, and the references. Section V is the substance: registration and marketing authorisation, pharmacovigilance, good-manufacturing-practice inspections, quality control and batch release of vaccines and sera, and authorisation of biomedical research. Section VI names the recognised authorities — WHO-listed authorities and maturity-level 3 and 4 authorities, and the international organisations Morocco belongs to. The guideline's own subject matter is medicines and vaccines, and it is ingested here because it is the jurisdiction's recognition instrument; the device-specific reliance mechanisms sit in the AMMPS device procedures rather than in this text. Two source artefacts are recorded rather than normalised: the cover reference is AMMPS-LD RE-001 while every page footer prints AMMPS-LD DG-001/ Ver. : 1.0, and section IX of the guide is followed only by the abbreviations and references the contents page promised, so the body and the contents page do not enumerate the same list.

AMMPS-LD RE-001, version 1.0 is the official identifier AMMPS uses for this instrument. Always confirm the current consolidated text and transition provisions with the official source before filing.